Key result
High preoperative Systemic Immune-inflammation Index (≥ 730) was an independent prognostic factor for worse cancer-specific survival (HR 10.7; 95% CI 1.12-103; p=0.039) and overall survival.
Why the study?
The predictive and prognostic value of preoperative Systemic Immune-inflammation Index in patients with radio-recurrent prostate cancer treated with salvage radical prostatectomy had not been established.
Does high preoperative Systemic Immune-inflammation Index predict adverse pathological features and survival in patients with radio-recurrent prostate cancer treated with salvage radical prostatectomy?
Cohort (n=214)
Yes
Does high preoperative Systemic Immune-inflammation Index predict adverse pathological features and survival in patients with radio-recurrent prostate cancer treated with salvage radical prostatectomy?
Hazard Ratio: 10.7 (95% CI 1.12–103)
p-value: p=0.039
High preoperative Systemic Immune-inflammation Index is associated with adverse pathological features and worse survival in patients undergoing salvage radical prostatectomy for radio-recurrent prostate cancer.
Purpose To examine the predictive and prognostic value of preoperative Systemic Immune-inflammation Index (SII) in patients with radio-recurrent prostate cancer (PCa) treated with salvage radical prostatectomy (SRP). Materials and methodsThis multicenter retrospective study included 214 patients with radio-recurrent PCa, treated with SRP between 2007 and 2015.SII was measured preoperatively (neutrophils × platelets/lymphocytes) and the cohort was stratified using optimal cut-off.Uni-and multivariable logistic and Cox regression analyses were performed to evaluate the predictive and prognostic value of SII as a preoperative biomarker.Results A total of 81 patients had high preoperative SII (≥ 730).On multivariable logistic regression modeling, high SII was predictive for lymph node metastases (OR 3.32, 95% CI 1.45-7.90,p = 0.005), and non-organ confined disease (OR 2.55, 95% CI 1.33-4.97,p = 0.005).In preoperative regression analysis, high preoperative SII was an independent prognostic factor for cancer-specific survival (CSS; HR 10.7, 95% CI 1.12-103, p = 0.039) and overall survival (OS; HR 8.57, 95% CI 2.70-27.2,p < 0.001).Similarly, in postoperative multivariable models, SII was associated with worse CSS (HR 22.11, 95% CI 1.23-398.12,p = 0.036) and OS (HR 5.98, 95% CI 1.67-21.44,p = 0.006).Notably, the addition of SII to preoperative reference models improved the C-index for the prognosis of CSS (89.5 vs. 80.5) and OS (85.1 vs 77.1). ConclusionsIn radio-recurrent PCa patients, high SII was associated with adverse pathological features at SRP and survival after SRP.Preoperative SII could help identify patients who might benefit from novel imaging modalities, multimodal therapy or a closer posttreatment surveillance.
No takes yet. Share an insight, caveat, or question.
Rajwa et al. (2021) conducted a cohort in radio-recurrent prostate cancer (n=214). High preoperative Systemic Immune-inflammation Index (SII ≥ 730) vs. Low preoperative SII (< 730) was evaluated on cancer-specific survival (CSS) (HR 10.7, 95% CI 1.12-103, p=0.039). High preoperative Systemic Immune-inflammation Index (≥ 730) was an independent prognostic factor for worse cancer-specific survival (HR 10.7; 95% CI 1.12-103; p=0.039) and overall survival.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: